Abstract | BACKGROUND: AIM: METHODS: RESULTS: The median dose of methotrexate was 13.75 mg/week (range 7.5-15) and the mean duration of methotrexate therapy was 49 months (range 11-126). At the end of follow-up pruritus in six of seven patients had improved, and fatigue in all patients had improved with the addition of methotrexate therapy ( pruritus: baseline 2.9 +/- 1.1 vs. end of treatment 0.6 +/- 1.5, P < or = 0.0175, and fatigue: baseline 3.0 +/- 0.8, vs. end of treatment 1.0 +/- 0.8, P < or = 0.0023). Improvement in symptoms was associated with a significant improvement in biochemical markers of cholestasis. No significant adverse effects of methotrexate were documented. CONCLUSIONS:
|
Authors | M A Babatin, F M Sanai, M G Swain |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 24
Issue 5
Pg. 813-20
(Sep 01 2006)
ISSN: 0269-2813 [Print] England |
PMID | 16918885
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cholagogues and Choleretics
- Enzyme Inhibitors
- Immunosuppressive Agents
- Ursodeoxycholic Acid
- gamma-Glutamyltransferase
- Alanine Transaminase
- Alkaline Phosphatase
- Rifampin
- Methotrexate
|
Topics |
- Adult
- Alanine Transaminase
(blood)
- Alkaline Phosphatase
(blood)
- Cholagogues and Choleretics
(therapeutic use)
- Drug Administration Schedule
- Enzyme Inhibitors
(therapeutic use)
- Fatigue
(drug therapy, etiology)
- Female
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Liver Cirrhosis, Biliary
(blood, complications, drug therapy)
- Methotrexate
(administration & dosage, adverse effects)
- Middle Aged
- Pruritus
(drug therapy, etiology)
- Rifampin
(therapeutic use)
- Treatment Outcome
- Ursodeoxycholic Acid
(therapeutic use)
- gamma-Glutamyltransferase
(blood)
|